| Dr Dillon Daniel Clarey, MD | |
|
4508 38th St Ste 210, Columbus, NE 68601-1668 | |
| (402) 562-4871 | |
| Not Available |
| Full Name | Dr Dillon Daniel Clarey |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Location | 4508 38th St Ste 210, Columbus, Nebraska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386133346 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 35818 (Nebraska) | Primary |
| Entity Name | Columbus Community Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821592205 PECOS PAC ID: 7517954944 Enrollment ID: O20120508000181 |
News Archive
Scil Technology GmbH, a biopharmaceutical company with core expertise in protein drug development, formulation and analytics, today announced that it has been awarded research funding by the German Federal Ministry of Education and Research (BMBF) under BMBF's KMU-innovativ scheme. The EUR 0.9 million grant supports Scil Technology's research program to explore the therapeutic potential of repellent proteins for the treatment of rheumatoid arthritis (RA).
e-MDs, an industry leader in the development and implementation of electronic health records and practice management solutions, is proud to announce it has increased its total employee count by 36%, expanding most all departments with both entry level and senior positions. e-MDs has also experienced a 36.5% increase in organic sales alone since the beginning of 2010.
The National Action Alliance for Suicide Prevention, a public-private partnership created in September to address the preventable public health tragedy of suicide, announced today the creation of its first three task forces.
Pregnancy hypertension, or Pre-eclampsia, is a complex disorder of pregnancy. Treatment of elevated blood pressure can manage the condition in the mother, but in severe cases delivery is needed, which can present a major problem to the baby if it is born prematurely.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that AVEO has regained worldwide rights from Merck (through its subsidiary, Schering Corporation) to develop and commercialize AV-299 (also known as SCH 900105), its anti-hepatocyte growth factor (HGF) antibody candidate.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Dillon Daniel Clarey, MD 4508 38th St Ste 210, Columbus, NE 68601-1668 Ph: (402) 562-4870 | Dr Dillon Daniel Clarey, MD 4508 38th St Ste 210, Columbus, NE 68601-1668 Ph: (402) 562-4871 |
News Archive
Scil Technology GmbH, a biopharmaceutical company with core expertise in protein drug development, formulation and analytics, today announced that it has been awarded research funding by the German Federal Ministry of Education and Research (BMBF) under BMBF's KMU-innovativ scheme. The EUR 0.9 million grant supports Scil Technology's research program to explore the therapeutic potential of repellent proteins for the treatment of rheumatoid arthritis (RA).
e-MDs, an industry leader in the development and implementation of electronic health records and practice management solutions, is proud to announce it has increased its total employee count by 36%, expanding most all departments with both entry level and senior positions. e-MDs has also experienced a 36.5% increase in organic sales alone since the beginning of 2010.
The National Action Alliance for Suicide Prevention, a public-private partnership created in September to address the preventable public health tragedy of suicide, announced today the creation of its first three task forces.
Pregnancy hypertension, or Pre-eclampsia, is a complex disorder of pregnancy. Treatment of elevated blood pressure can manage the condition in the mother, but in severe cases delivery is needed, which can present a major problem to the baby if it is born prematurely.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that AVEO has regained worldwide rights from Merck (through its subsidiary, Schering Corporation) to develop and commercialize AV-299 (also known as SCH 900105), its anti-hepatocyte growth factor (HGF) antibody candidate.
› Verified 7 days ago